Intravenous Tirofiban After Delayed Thrombolysis in Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 852 participants.

Also called NCT07111806

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 852 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07111806
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07111806. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-01 (anticipated); primary completion 2028-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intravenous Tirofiban After Delayed Thrombolysis in Stroke
Acronym
PEARL-TIRO
Condition
Acute Ischemic Stroke
Intervention (Drug)
Tirofiban
Intervention (Drug)
Placebo
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct07111806
Content hash
74bcaec8e796fe0af54c2cf728aebd14ca11c76aeea4d02f594e84530429f0b3